Report Says BRIC Countries Must Be Dealt With Individually, Not As Group
This article was originally published in PharmAsia News
Although global drug manufacturers may lump Brazil, Russia, India and China under the same BRIC rubric of emerging-market opportunities, each offers a special challenge as it deals with its health-care infrastructure.
You may also be interested in...
Hiring travails, inspection pre-announcement, lack of translators highlighted in congressional hearing on FDA foreign inspections.
The court included its decision on Amarin’s ’s petition for a writ of certiorari among the single-line denials of nearly 200 appeals to consider decisions in civil litigation and convictions in criminal cases. However, Amarin still eyes curbing competition from omega-3 supplements.
Senate's Over-the-Counter Monograph Safety, Innovation, and Reform Act goes next for consideration by House, which has had a bill by the same title on its floor for a vote since it was passed by Energy and Commerce Committee in late June.